Octreotide as first-line treatment for women with metastatic breast cancer

James N. Ingle, Carl G. Kardinal, Vera Jean Suman, James E. Krook, Alan K. Hatfield

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

Original languageEnglish (US)
Pages (from-to)235-237
Number of pages3
JournalInvestigational New Drugs
Volume14
Issue number2
StatePublished - 1996

Fingerprint

Octreotide
Implosive Therapy
Breast Neoplasms
Somatostatin
Treatment Failure
Human Activities
Cell Culture Techniques
Therapeutics

Keywords

  • Metastatic breast cancer
  • Octreotide

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Ingle, J. N., Kardinal, C. G., Suman, V. J., Krook, J. E., & Hatfield, A. K. (1996). Octreotide as first-line treatment for women with metastatic breast cancer. Investigational New Drugs, 14(2), 235-237.

Octreotide as first-line treatment for women with metastatic breast cancer. / Ingle, James N.; Kardinal, Carl G.; Suman, Vera Jean; Krook, James E.; Hatfield, Alan K.

In: Investigational New Drugs, Vol. 14, No. 2, 1996, p. 235-237.

Research output: Contribution to journalArticle

Ingle, JN, Kardinal, CG, Suman, VJ, Krook, JE & Hatfield, AK 1996, 'Octreotide as first-line treatment for women with metastatic breast cancer', Investigational New Drugs, vol. 14, no. 2, pp. 235-237.
Ingle, James N. ; Kardinal, Carl G. ; Suman, Vera Jean ; Krook, James E. ; Hatfield, Alan K. / Octreotide as first-line treatment for women with metastatic breast cancer. In: Investigational New Drugs. 1996 ; Vol. 14, No. 2. pp. 235-237.
@article{e803b41728d24b9a87b2f325643d3098,
title = "Octreotide as first-line treatment for women with metastatic breast cancer",
abstract = "Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.",
keywords = "Metastatic breast cancer, Octreotide",
author = "Ingle, {James N.} and Kardinal, {Carl G.} and Suman, {Vera Jean} and Krook, {James E.} and Hatfield, {Alan K.}",
year = "1996",
language = "English (US)",
volume = "14",
pages = "235--237",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - Octreotide as first-line treatment for women with metastatic breast cancer

AU - Ingle, James N.

AU - Kardinal, Carl G.

AU - Suman, Vera Jean

AU - Krook, James E.

AU - Hatfield, Alan K.

PY - 1996

Y1 - 1996

N2 - Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

AB - Octreotide is a synthetic somatostatin analogue which has shown inhibitory activity against human breast cancer cells in culture. Ten patients with metastatic breast cancer and no prior hormonal therapy exposure received octreotide at 150 μg subcutaneously thrice daily. No objective responses were observed and the median time to treatment failure was short at 57 days.

KW - Metastatic breast cancer

KW - Octreotide

UR - http://www.scopus.com/inward/record.url?scp=0029818962&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029818962&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 235

EP - 237

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -